Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million

Core Viewpoint - Rakovina Therapeutics Inc. has announced an upsized financing plan totaling approximately $2 million, which includes a convertible debenture and a common share private placement to support near-term operations [1][4]. Financing Details - The financing consists of a non-brokered private placement of an unsecured convertible debenture for $1.0 million, along with two million common share purchase warrants, with each warrant exercisable at $0.20 per share until January 28, 2029 [2][9]. - Concurrently, the company proposes to offer up to 8,333,334 common shares at a price of $0.12 per share, aiming for additional gross proceeds of up to approximately $1.0 million [3]. Use of Proceeds - The aggregate gross proceeds from the private placements will be utilized for near-term working capital to support ongoing corporate activities and strategic initiatives while evaluating longer-term financing alternatives [4]. Regulatory Approvals - The closing of the private placements is contingent upon obtaining all necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [5]. Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI-powered drug discovery technologies, specifically targeting the DNA-damage response [6][7].